CD274 and nasopharyngeal carcinoma: ICPi targeting programmed death receptor 1 (PD-1) or its ligand (PDL1) or cytotoxic T-cell lymphocyte-associated protein 4 (CTLA-4) have shown effectiveness in treating recurrent/metastatic NPC [123,124,125,126].